Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease

O Badawy; A S Wierzbicki; R Hilton

Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

This case report describes the treatment of a patient with end-stage renal disease on peritoneal dialysis who presented with triglycerides of 35 mmol/l, cholesterol of 14 mmol/l and visible chylomicronaemia. She was only partially responsive to statin and fibrate monotherapy, so was treated with fibrate-statin combination therapy Daily fibrate therapy resulted in a myositis, but once-weekly fibrate therapy with nocturnal daily statin therapy resulted in a reduction in total cholesterol of 49%, triglycerides of 82% and raised HDL by 52%, enabling her to achieve a target LDL of 3 mmol/l and HDL of 1 mmol/l. Combination therapy with low frequency (weekly) fibrate administration and daily statin treatment may provide a means to control the severe hypertriglyceridaemia of patients with renal disease.

Original language	English
Pages (from-to)	249 - 251
Number of pages	3
Journal	International Journal of Clinical Practice
Volume	57
Issue number	3
Publication status	Published - Apr 2003

Cite this

@article{a2fbdf36c9ba48759634b79495c9653a,

title = "Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease",

abstract = "This case report describes the treatment of a patient with end-stage renal disease on peritoneal dialysis who presented with triglycerides of 35 mmol/l, cholesterol of 14 mmol/l and visible chylomicronaemia. She was only partially responsive to statin and fibrate monotherapy, so was treated with fibrate-statin combination therapy Daily fibrate therapy resulted in a myositis, but once-weekly fibrate therapy with nocturnal daily statin therapy resulted in a reduction in total cholesterol of 49%, triglycerides of 82% and raised HDL by 52%, enabling her to achieve a target LDL of 3 mmol/l and HDL of 1 mmol/l. Combination therapy with low frequency (weekly) fibrate administration and daily statin treatment may provide a means to control the severe hypertriglyceridaemia of patients with renal disease.",

author = "O Badawy and Wierzbicki, {A S} and R Hilton",

year = "2003",

month = apr,

language = "English",

volume = "57",

pages = "249 -- 251",

journal = "International Journal of Clinical Practice",

issn = "1742-1241",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease

AU - Badawy, O

AU - Wierzbicki, A S

AU - Hilton, R

PY - 2003/4

Y1 - 2003/4

N2 - This case report describes the treatment of a patient with end-stage renal disease on peritoneal dialysis who presented with triglycerides of 35 mmol/l, cholesterol of 14 mmol/l and visible chylomicronaemia. She was only partially responsive to statin and fibrate monotherapy, so was treated with fibrate-statin combination therapy Daily fibrate therapy resulted in a myositis, but once-weekly fibrate therapy with nocturnal daily statin therapy resulted in a reduction in total cholesterol of 49%, triglycerides of 82% and raised HDL by 52%, enabling her to achieve a target LDL of 3 mmol/l and HDL of 1 mmol/l. Combination therapy with low frequency (weekly) fibrate administration and daily statin treatment may provide a means to control the severe hypertriglyceridaemia of patients with renal disease.

AB - This case report describes the treatment of a patient with end-stage renal disease on peritoneal dialysis who presented with triglycerides of 35 mmol/l, cholesterol of 14 mmol/l and visible chylomicronaemia. She was only partially responsive to statin and fibrate monotherapy, so was treated with fibrate-statin combination therapy Daily fibrate therapy resulted in a myositis, but once-weekly fibrate therapy with nocturnal daily statin therapy resulted in a reduction in total cholesterol of 49%, triglycerides of 82% and raised HDL by 52%, enabling her to achieve a target LDL of 3 mmol/l and HDL of 1 mmol/l. Combination therapy with low frequency (weekly) fibrate administration and daily statin treatment may provide a means to control the severe hypertriglyceridaemia of patients with renal disease.

UR - http://www.scopus.com/inward/record.url?scp=0037397792&partnerID=8YFLogxK

M3 - Article

SN - 1742-1241

VL - 57

SP - 249

EP - 251

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

IS - 3

ER -

Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease

Abstract

Other files and links

Fingerprint

Cite this